Dermatologic Manifestations of Multiple Endocrine Neoplasia Type 1 (MEN1) Follow-up

Updated: Nov 03, 2020
  • Author: Thomas N Darling, MD, PhD; Chief Editor: Dirk M Elston, MD  more...
  • Print


Endocrine tumors in MEN1

Tumors may hypersecrete hormone, causing hypercalcemia and recurrent nephrolithiasis (hyperparathyroidism), Zollinger-Ellison syndrome (hypergastrinemia), hypoglycemia (hyperinsulinemia), amenorrhea (hyperprolactinemia), or acromegaly (excess growth hormone). Tumors of the pituitary gland may cause symptoms by mass effects. Pancreatic endocrine tumors, particularly gastrinomas, become malignant in about 50% of patients with MEN1. Untreated, patients may die from peptic ulcer disease, metastatic endocrine pancreatic carcinoma, or foregut carcinoid malignancy.

Cutaneous tumors in MEN1

Angiofibromas, collagenomas, and lipomas do not typically cause symptoms, and they are mostly of cosmetic concern.


Patient Education

For patient education resources related to multiple endocrine neoplasia type 1 (MEN1), see the Endocrine System Center, as well as Anatomy of the Endocrine System.